-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UAQ6t805qyPOGiKp2uUxIXmAUGxgDOZGcHwKG5Mc1f0Bgpxhk9l8VmSm/y6PIsSh NaPLb052WhRgOjwOjPyW2A== /in/edgar/work/20000627/0000912057-00-029925/0000912057-00-029925.txt : 20000920 0000912057-00-029925.hdr.sgml : 20000920 ACCESSION NUMBER: 0000912057-00-029925 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000627 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND II,L.P. GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND L P GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF PARTNERS L.P. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN BIOGENETIC SCIENCES INC CENTRAL INDEX KEY: 0000856984 STANDARD INDUSTRIAL CLASSIFICATION: [2836 ] IRS NUMBER: 112655906 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-45379 FILM NUMBER: 661817 BUSINESS ADDRESS: STREET 1: 1375 AKRON STREET STREET 2: P O BOX 1001 CITY: COPIAGUE STATE: NY ZIP: 11726 BUSINESS PHONE: 5167892600 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: [6282 ] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 MAIL ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 SC 13D/A 1 sc13da.txt SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ------------ SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (AMENDMENT NO. 1)(1) AMERICAN BIOGENETIC SCIENCES, INC. ---------------------------------- (Name of Issuer) Common Stock ---------------------------- (Title of Class of Securities) 024611 10 5 ------------ (CUSIP Number) Hope Flack BVF Partners L.P 227 West Monroe Street, Suite 4800 Chicago, Illinois 60606 (312) 263-7777 -------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 16, 2000 ------------- (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / / NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. SEE Rule 13d-1(a) for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 8 Pages) - -------------------- (1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, SEE the NOTES). CUSIP No. 024611 10 5 13D Page 2 of 9 Pages - ------------------------------------------------------------------------------- (1) Names of Reporting Person: BIOTECHNOLOGY VALUE FUND, L.P. I.R.S. Identification No. of Above Person (Entities Only): - ------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) /X/ of a Group* (b) / / - ------------------------------------------------------------------------------- (3) SEC Use Only - ------------------------------------------------------------------------------- (4) Citizenship or Place of Organization DELAWARE - ------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power Beneficially Owned 0 by Each Reporting -------------------------------------------------- Person With (6) Shared Voting Power 4,200,000 -------------------------------------------------- (7) Sole Dispositive Power 0 -------------------------------------------------- (8) Shared Dispositive Power 4,200,000 - ------------------------------------------------------------------------------- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 4,200,000 - ------------------------------------------------------------------------------- (10) Check box if the Aggregate Amount in Row (9) Excludes Certain Shares* / / - ------------------------------------------------------------------------------- (11) Percent of Class Represented by Amount in Row (9) 7.7% - ------------------------------------------------------------------------------- (12) Type of Reporting Person* PN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! CUSIP No. 024611 10 5 13D Page 3 of 9 Pages - ------------------------------------------------------------------------------- (1) Names of Reporting Person. BIOTECHNOLOGY VALUE FUND II, L.P. I.R.S. Identification No. of Above Person (Entities only) - ------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) /X/ of a Group* (b) / / - ------------------------------------------------------------------------------- (3) SEC Use Only - ------------------------------------------------------------------------------- (4) Citizenship or Place of Organization DELAWARE - ------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power Beneficially Owned 0 by Each Reporting -------------------------------------------------- Person With (6) Shared Voting Power 7,200,000 -------------------------------------------------- (7) Sole Dispositive Power 0 -------------------------------------------------- (8) Shared Dispositive Power 7,200,000 - ------------------------------------------------------------------------------- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 7,200,000 - ------------------------------------------------------------------------------- (10) Check box if the Aggregate Amount in Row (9) Excludes Certain Shares* / / - ------------------------------------------------------------------------------- (11) Percent of Class Represented by Amount in Row (9) 13.2% - ------------------------------------------------------------------------------- (12) Type of Reporting Person* PN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! CUSIP No. 024611 10 5 13D Page 4 of 9 Pages - ------------------------------------------------------------------------------- (1) Names of Reporting Person. BVF PARTNERS L.P. I.R.S. Identification No. of Above Person (Entities only) - ------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) /X/ of a Group* (b) / / - ------------------------------------------------------------------------------- (3) SEC Use Only - ------------------------------------------------------------------------------- (4) Citizenship or Place of Organization DELAWARE - ------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power Beneficially Owned 0 by Each Reporting -------------------------------------------------- Person With (6) Shared Voting Power 12,000,000 -------------------------------------------------- (7) Sole Dispositive Power 0 -------------------------------------------------- (8) Shared Dispositive Power 12,000,000 - ------------------------------------------------------------------------------- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 12,000,000 - ------------------------------------------------------------------------------- (10) Check box if the Aggregate Amount in Row (9) Excludes Certain Shares* / / - ------------------------------------------------------------------------------- (11) Percent of Class Represented by Amount in Row (9) 21.9% - ------------------------------------------------------------------------------- (12) Type of Reporting Person* PN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! CUSIP No. 024611 10 5 13D Page 5 of 9 Pages - ------------------------------------------------------------------------------- (1) Names of Reporting Person. BVF INC. I.R.S. Identification No. of Above Person (Entities only) - ------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) /X/ of a Group* (b) / / - ------------------------------------------------------------------------------- (3) SEC Use Only - ------------------------------------------------------------------------------- (4) Citizenship or Place of Organization DELAWARE - ------------------------------------------------------------------------------- Number of Shares (5) Sole Voting Power Beneficially Owned 0 by Each Reporting -------------------------------------------------- Person With (6) Shared Voting Power 12,000,000 -------------------------------------------------- (7) Sole Dispositive Power 0 -------------------------------------------------- (8) Shared Dispositive Power 12,000,000 - ------------------------------------------------------------------------------- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 12,000,000 - ------------------------------------------------------------------------------- (10) Check box if the Aggregate Amount in Row (9) Excludes Certain Shares* / / - ------------------------------------------------------------------------------- (11) Percent of Class Represented by Amount in Row (9) 21.9% - ------------------------------------------------------------------------------- (12) Type of Reporting Person* IA, CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! CUSIP No. 024611 10 5 13D Page 6 of 9 Pages This Amendment (this "Amendment") to the Statement on Schedule 13D dated February 7, 2000 (the "Statement") is being filed with the Securities and Exchange Commission on behalf of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF"), Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2"), BVF Partners L.P., a Delaware limited partnership ("Partners"), and BVF Inc., a Delaware corporation ("BVF Inc." and, together with BVF, BVF2 and Partners, the "Reporting Persons") with respect to Series A Convertible Preferred Stock (the "Preferred Stock) and Warrants (the "Warrants") of American Biogenetic Sciences, Inc., a Delaware corporation ("American Biogenetic"). Class A Common Stock, par value $0.001 per share, (the "Common Stock," and collectively with the Preferred Stock and the Warrants, the "Securities") underlies both the Preferred Stock and Warrants. The principal executive office of American Biogenetic is located at 1375 Akron Street, Copiague, New York 11726. Item 4 is hereby amended to read in its entirety as follows: ITEM 4. PURPOSE OF TRANSACTIONS. The purpose of the acquisitions of the Securities reported herein was for investment. The Reporting Persons have been assisting American Biogenetic in various measures intended to enhance shareholder value, including introducing opportunities for strategic alliances, mergers and acquisitions. The Reporting Persons may have an interest in those companies being introduced to American Biogenetic. The Reporting Persons did not at the time of such acquisitions of the Securities, and do not presently, have any plan to acquire control of American Biogenetic. The Reporting Persons may acquire or dispose of additional Securities from time to time. Item 7 is hereby amended to read in its entirety as follows: ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit 1 - Agreement Regarding Joint Filing CUSIP No. 024611 10 5 13D Page 7 of 9 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment is true, complete and correct. Dated: June 26, 2000 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert ---------------------------- Mark N. Lampert President BIOTECHNOLOGY VALUE FUND II, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert ---------------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ Mark N. Lampert ---------------------------- Mark N. Lampert President BVF INC. By: /s/ Mark N. Lampert ---------------------------- Mark N. Lampert President EXHIBIT 1 AGREEMENT REGARDING JOINT FILING The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, Biotechnology Value Fund II, L.P., a Delaware limited partnership, BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the Amendment to the Statement containing the information required by Schedule 13D, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any further amendments or supplements thereto shall also be filed on behalf of each of them. Dated: June 26, 2000 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert ---------------------------- Mark N. Lampert President BIOTECHNOLOGY VALUE FUND II, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert ---------------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ Mark N. Lampert ---------------------------- Mark N. Lampert President BVF INC. By: /s/ Mark N. Lampert ---------------------------- Mark N. Lampert President -----END PRIVACY-ENHANCED MESSAGE-----